Business Description
ABL Diagnostics
ISIN : FR001400AHX6
Total Employee Number:
21Compare
Compare
Traded in other countries / regions
ABLD.France9BK0.Germany IPO Date
1989-07-27Description
ABL Diagnostics is a diagnostic and medical software company. The group has focused on the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. It also develops, manufactures, and markets kits for clinical specimen collection.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.59 | |||||
Equity-to-Asset | 0.59 | |||||
Debt-to-Equity | 0.3 | |||||
Debt-to-EBITDA | 2.22 | |||||
Interest Coverage | 3.92 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 6.23 | |||||
Beneish M-Score | -2.64 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -7.3 | |||||
3-Year EBITDA Growth Rate | 16.3 | |||||
3-Year EPS without NRI Growth Rate | 13 | |||||
3-Year Book Growth Rate | 4.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 82.91 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 59.14 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 55.34 | |||||
9-Day RSI | 50.85 | |||||
14-Day RSI | 48.35 | |||||
3-1 Month Momentum % | 9.15 | |||||
6-1 Month Momentum % | -19.27 | |||||
12-1 Month Momentum % | -42.59 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.41 | |||||
Quick Ratio | 2.12 | |||||
Cash Ratio | 0.34 | |||||
Days Inventory | 993.43 | |||||
Days Sales Outstanding | 208.81 | |||||
Days Payable | 1833.93 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 4.14 | |||||
Dividend Payout Ratio | 0.82 | |||||
Forward Dividend Yield % | 4.14 | |||||
5-Year Yield-on-Cost % | 4.14 | |||||
3-Year Average Share Buyback Ratio | 0.1 | |||||
Shareholder Yield % | 6.75 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 95.3 | |||||
Operating Margin % | 4.17 | |||||
Net Margin % | 14.2 | |||||
EBITDA Margin % | 14.58 | |||||
FCF Margin % | 10.29 | |||||
OCF Margin % | 21.68 | |||||
ROE % | 13.43 | |||||
ROA % | 8.26 | |||||
ROIC % | 3.15 | |||||
3-Year ROIIC % | 491.49 | |||||
ROC (Joel Greenblatt) % | 9.81 | |||||
ROCE % | 4.34 | |||||
Years of Profitability over Past 10-Year | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 43.61 | |||||
Forward PE Ratio | 29.33 | |||||
PE Ratio without NRI | 43.61 | |||||
Shiller PE Ratio | 31.55 | |||||
Price-to-Owner-Earnings | 49.26 | |||||
PS Ratio | 6.16 | |||||
PB Ratio | 5.6 | |||||
Price-to-Tangible-Book | 9.17 | |||||
Price-to-Free-Cash-Flow | 59.11 | |||||
Price-to-Operating-Cash-Flow | 28.3 | |||||
EV-to-EBIT | 108.38 | |||||
EV-to-EBITDA | 43.12 | |||||
EV-to-Revenue | 6.28 | |||||
EV-to-FCF | 61.09 | |||||
Price-to-GF-Value | 0.35 | |||||
Price-to-Projected-FCF | 12.09 | |||||
Price-to-Graham-Number | 4.22 | |||||
| Price-to-Net-Current-Asset-Value | 10.23 | |||||
Earnings Yield (Greenblatt) % | 0.92 | |||||
FCF Yield % | 1.67 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ABL Diagnostics Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 6.95 | ||
| EPS (TTM) (€) | 0.061 | ||
| Beta | 1.7918 | ||
| 3-Year Sharpe Ratio | -0.08 | ||
| 3-Year Sortino Ratio | -0.13 | ||
| Volatility % | 68.08 | ||
| 14-Day RSI | 48.35 | ||
| 14-Day ATR (€) | 0.234151 | ||
| 20-Day SMA (€) | 2.574 | ||
| 12-1 Month Momentum % | -42.59 | ||
| 52-Week Range (€) | 2.12 - 5.75 | ||
| Shares Outstanding (Mil) | 16.07 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ABL Diagnostics Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ABL Diagnostics Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| EUR 0.110000 Cash Dividend | 2026-07-03 | 2.64 (-5.04%) | ||
| EUR 0.050000 Cash Dividend | 2025-06-27 | 5.45 (+0.93%) | ||
| 8:1 Stock Split | 2022-05-18 | 3.25 (+0.00%) |
Show
Entries
ABL Diagnostics Frequently Asked Questions
What is ABL Diagnostics(XPAR:ABLD)'s stock price today?
The current price of XPAR:ABLD is €2.66. The 52 week high of XPAR:ABLD is €5.75 and 52 week low is €2.12.
When is next earnings date of ABL Diagnostics(XPAR:ABLD)?
The next earnings date of ABL Diagnostics(XPAR:ABLD) is .
Does ABL Diagnostics(XPAR:ABLD) pay dividends? If so, how much?
The Dividend Yield %  of ABL Diagnostics(XPAR:ABLD) is 4.14% (As of Today), Highest Dividend Payout Ratio of ABL Diagnostics(XPAR:ABLD) was 0.82. The lowest was 0.81. And the median was 0.81. The  Forward Dividend Yield % of ABL Diagnostics(XPAR:ABLD) is 4.14%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on ABL Diagnostics
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers